844502-63-2

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Thiophenedicarboxylic acid, 2-amino-, 3-ethyl 4-methyl ester is used as a synthetic intermediate for the preparation of various pharmaceutical compounds. Its unique structure and functional groups enable the development of molecules with specific biological activities, making it a valuable asset in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 3,4-thiophenedicarboxylic acid, 2-amino-, 3-ethyl 4-methyl ester is employed as a key component in the synthesis of agrochemicals. Its properties allow for the creation of compounds with pesticidal or herbicidal activities, contributing to the development of effective crop protection solutions.
Used in Organic Synthesis:
3,4-Thiophenedicarboxylic acid, 2-amino-, 3-ethyl 4-methyl ester is utilized as a building block in organic synthesis, allowing for the construction of a wide range of organic compounds. Its versatility and reactivity make it a valuable tool for chemists in various research and industrial applications.

Upstream product

• 600-22-6 pyruvic acid methyl ester 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 1353498-44-8 ethyl 4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxylate 
• 1456890-20-2 N-(4-formylbenzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-19-9 C₁₇H₁₅N₃O₄S 
• 1456890-41-7 N-{4-[(4-hydroxypiperidin-1-yl)methyl]benzyl}-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-38-2 N-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]methyl}benzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-37-1 4-oxo-N-{4-[(3-oxopiperazin-1-yl)methyl]benzyl}-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-35-9 N-(4-{[(3S)-3-hydroxypyrrolidin-1-yl]methyl}benzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-34-8 N-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}benzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-33-7 N-{4-[(3-hydroxypyrrolidin-1-yl)methyl]benzyl}-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-32-6 4-oxo-N-[4-(pyrrolidin-1-ylmethyl)benzyl]-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-30-4 C₁₉H₂₀N₆O₂S 
• 1456890-27-9 N-(4-{[(2-hydroxyethyl)amino]methyl}benzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-26-8 N-(4-{[(2-methoxyethyl)amino]methyl}benzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1456890-25-7 4-oxo-N-{4-[(propylamino)methyl]benzyl}-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 

Relevant academic research and scientific papers

Molecular Weight Engineering in High-Performance Ambipolar Emissive Mesopolymers

Mesopolymers with high solubility, free of structural defects, and negligible batch-to-batch variation open a new avenue for organic optoelectronics. Organic light emitting transistors that combine the functions of organic light-emitting diodes and organic field-effect transistors. However, charge transport ability and light emitting strength are contradictory within one conjugated polymer. Herein, three low-molecular-weight mesopolymers with thienopyrroledione–benzothiadiazole repeating units (meso-TBTF) were obtained. The mesopolymers show strong solid-state emission and high ambipolar carrier mobility. The molecular weights of meso-TBTF can be tuned by polymerization temperature. The mesopolymers have photoluminescence quantum yields (PLQY) of about 50 % in solution and 10 % in solid state. Polymer light emitting diodes of this material are fabricated to explore its potential use in optoelectronic devices.

Preparation process 2-5 - thiophene dicarboxylic acid

The invention relates to 2-5 - thiophene dicarboxylic acid preparation process comprising the following steps: preparing intermediate product 2 - aminothiophene -3, 4 -dicarboxylic acid 3 - ethyl ester 4 - methyl ester; and obtaining the final product 2 - and -3 thiophene dicarboxylic acid through the obtained intermediate product thiophene 4 - and 3 - 3 - dicarboxylic acid 4 - ethyl ester 4 -3 methyl ester, and finally obtaining the intermediate product thienothiophene 5 - 2 4 - 4 -3 diethyl 4 - carboxylate and 3 - methyl ethyl ester. The method disclosed by the invention is low in price, mild in reaction and high in yield, does not need to be purified by a silica gel column, and is very suitable for amplification production.

Structural Insight into Aggregation and Orientation of TPD-Based Conjugated Polymers for Efficient Charge-Transporting Properties

In this study, we obtained a new structural insight into the charge-transporting properties in TPD-based polymers that cannot be solely explained in terms of the type of orientation. We synthesized two types of copolymers comprising mono-TPD or bis-TPD as the accepting unit. Although the planarity and energy levels are similar with the mono-TPD unit, the aggregation state is quite different, and the X-aggregation tendency seems to be stronger when the bis-TPD unit is incorporated. In the case of TPD1, an effective π-πorbital overlap is found to originate from the H-aggregates, and 3D charge transport pathways are formed with a bimodal orientation of edge-on and face-on, resulting in an efficient charge transportation (1.84 cm2·V-1·s-1 of hole and 0.31 cm2·V-1·s-1 of electron). In contrast, despite the well-aligned edge-on orientation of TPD2, it exhibited a relatively very low mobility and splitted emission characteristics in photoluminescence spectra because of the tilted intermolecular stacking pattern with an X-shape (0.015 cm2·V-1·s-1 for hole and 0.16 cm2·V-1·s-1 for electron). An overall characterization of the semiconducting polymers was performed, and it was found that the type of aggregation in the final thin films, such as H- or X-aggregation, is indeed important and perhaps more important than the orientation to obtain polymers with a high charge carrier mobility.

Thienopyrimidinone Derivatives That Inhibit Bacterial tRNA (Guanine37- N1)-Methyltransferase (TrmD) by Restructuring the Active Site with a Tyrosine-Flipping Mechanism

Among the >120 modified ribonucleosides in the prokaryotic epitranscriptome, many tRNA modifications are critical to bacterial survival, which makes their synthetic enzymes ideal targets for antibiotic development. Here we performed a structure-based design of inhibitors of tRNA-(N1G37) methyltransferase, TrmD, which is an essential enzyme in many bacterial pathogens. On the basis of crystal structures of TrmDs from Pseudomonas aeruginosa and Mycobacterium tuberculosis, we synthesized a series of thienopyrimidinone derivatives with nanomolar potency against TrmD in vitro and discovered a novel active site conformational change triggered by inhibitor binding. This tyrosine-flipping mechanism is uniquely found in P. aeruginosa TrmD and renders the enzyme inaccessible to the cofactor S-adenosyl-l-methionine (SAM) and probably to the substrate tRNA. Biophysical and biochemical structure-activity relationship studies provided insights into the mechanisms underlying the potency of thienopyrimidinones as TrmD inhibitors, with several derivatives found to be active against Gram-positive and mycobacterial pathogens. These results lay a foundation for further development of TrmD inhibitors as antimicrobial agents.

COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

Selective inhibitors of bacterial t-RNA-(N1G37) methyltransferase (TrmD) that demonstrate novel ordering of the lid domain

The tRNA-(N1G37) methyltransferase (TrmD) is essential for growth and highly conserved in both Gram-positive and Gram-negative bacterial pathogens. Additionally, TrmD is very distinct from its human orthologue TRM5 and thus is a suitable target for the design of novel antibacterials. Screening of a collection of compound fragments using Haemophilus influenzae TrmD identified inhibitory, fused thieno-pyrimidones that were competitive with S-adenosylmethionine (SAM), the physiological methyl donor substrate. Guided by X-ray cocrystal structures, fragment 1 was elaborated into a nanomolar inhibitor of a broad range of Gram-negative TrmD isozymes. These compounds demonstrated no activity against representative human SAM utilizing enzymes, PRMT1 and SET7/9. This is the first report of selective, nanomolar inhibitors of TrmD with demonstrated ability to order the TrmD lid in the absence of tRNA.

Low-cost synthesis and physical characterization of thieno[3,4-c]pyrrole-4, 6-dione-based polymers

The improved synthesis of thieno[3,4-c]pyrrole-4,6-dione (TPD) monomers, including Gewald thiophene ring formation, a Sandmeyer-type reaction, and neat condensation with an amine, is presented. This protocol enables faster, cheaper, and more efficient preparation of TPD units in comparison to traditional methods. Furthermore, a series of TPD homo- and pseudohomopolymers bearing various alkyl chains was synthesized via a direct heteroarylation polymerization (DHAP) procedure. UV-visible absorption and powder X-ray diffraction measurements revealed the relationship between the ratio of branched to linear alkyl chains and the optoelectronic properties of the polymers as well as their packing in the solid state.

Synthesis and characterization of 5-octylthieno[3,4-c ]pyrrole-4,6-dione derivatives as new monomers for conjugated copolymers

An efficient route for the synthesis of 1-iodo-5-octyl-4H-thieno[3,4-c] pyrrole-4,6(5H)-dione as a key intermediate to build new electron-deficient monomers and related conjugated polymers is reported. Along these lines, two new low bandgap copolymers were synthesized from Stille or Suzuki coupling. These polymers were characterized and their properties compared to those of analogous conjugated polymers.

Thienopyridones as AMPK activators for the treatment of diabetes and obesity

The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.